SNPMiner Trials (Home Page)
Report for Mutation A2063G
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 2 clinical trials
Clinical Trials
1 Studies on Macrolide-resistant Mycoplasma Pneumoniae in Taiwan- A Randomized Control Trial and MLVA Analysis
A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.
NCT03530319 Pneumonia, Mycoplasma Drug: Doxycycline Drug: Azithromycin MeSH:Mycoplasma Infections Pneumonia, Mycoplasma Pneumonia Pleuropneumonia
HPO:Pneumonia
In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---
Primary Outcomes
Description: The timing (days) when fever subsides after treatment
Measure: Defervescence Time: Up to 10 daysSecondary Outcomes
Description: The length of hospitalization
Measure: Hospital stay Time: Up to 2 weeks2 Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development
A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.
NCT03911440 Atypical Pneumonia Drug: Doxycycline Drug: Azithromycin MeSH:Mycoplasma Infections Pneumonia, Mycoplasma Pneumonia Pleuropneumonia
HPO:Pneumonia
In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---
Primary Outcomes
Description: The timing (days) when fever subsides after treatment
Measure: Defervescence Time: Up to 10 daysSecondary Outcomes
Description: The length of hospitalization
Measure: Hospital stay Time: Up to 2 weeks